That's the beauty of AVXL, they ran just a small non-optimized Ph 2a trial to find optimal dosing and max tolerable dose, yet they've unexpectedly been getting very good efficacy results at every 3 month interval for, what will be, 15 monnths.
They had patients on different dosages. Assuming all the drop outs reason for dropping out was related to the Anavex drug, the drop outs that cited dizziness, they were prolly on too high a dosage, whereas that same dosage on another person in the trial was/is fine. The Ariana and PK/PD analysis is sussing that all out (what dosages are tolerated and most effective for different types of people). Ph 2a wasn't even optimized or powered, yet Anavex saw unexpected, stat sig efficacy results; that's unprecedented at 57 weeks (and soon 15 mos). I like how Anavex is using biomarkers in their trials. Is Neurotrope for Ph 2 and Ph 3? They should be b/c P300 is correlated with synapse function, which is the entire focus of bryostatin. I'll assume they are. I also like how Anavex attracts others to help fund their trials: the Australian govt and a couple different foundations. Biogen's studying Anavex's drug and if they like it for MS there will be a deal struck at some point. Anavex has a nice pipeline and their drugs are targetting so many different, both related and unrelated, diseases from insomnia to depression to MS to epilepsy to cancer, etc. And their drug 3-71 is even a better drug than 2-73
